Clinical Trials Logo

Clinical Trial Summary

ST-elevation myocardial infarction is a major cause of morbidity and mortality worldwide. ST-elevation myocardial infarction damages the regional myocardium that undergoes ischemia and necrosis, resulting in impairment of both systolic and diastolic functions of the heart. Left ventricular function and myocardial infarct size both serve as the main determinants Of patients' outcome after myocardial infarction. Timely management of ST-elevation myocardial infarction, using reperfusion therapy, including fibrinolysis and primary percutaneous coronary intervention, leads to a better outcome for these patients.


Clinical Trial Description

Reperfusion failure is attributed to different factors, including diabetes. Several mechanisms have been proposed for the harmful effects of hyperglycemia after acute myocardial infarction. Association of hyperglycemia with the activation of blood coagulation has been well studied; it could induce a shortening of the fibrinogen half-life, increase in fibrinopeptide A, fragments of pro-thrombin in factor VII, and platelet aggregation, all of which could lead to increased activation of thrombosis. Hyperglycemia at admission is associated with increased levels of inflammatory markers, enhanced expression of cytotoxic T-cells, and reduced expression of cytotoxic T-lymphocyte-associated protein 4, indicating its association with increased inflammatory immune process after acute myocardial infarction. It also could be associated with endothelial dysfunction, oxidative stress, and possibly, abolition of protective ischemic preconditioning. Other possible mechanism of harmful effects of acute hyperglycemia is microvascular dysfunction after coronary revascularization.

Studying the influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction, GUSTO-I trial showed that patients with diabetes mellitus have a significantly increased risk of both early and late mortality, which may be attributed to more advanced coronary artery disease and co-morbidities.

Results of the HORIZONS-AMI study showed that patients with newly diagnosed diabetes mellitus had similarly poor prognosis after primary percutaneous coronary intervention in ST-elevation myocardial infarction patients as those with previously established diabetes mellitus, newly diagnosed diabetes mellitus was based on HgbA1c levels following admission and did not assess for blood glucose levels at admission or during hospital stay.

Regarding the effect of diabetes mellitus on left ventricular systolic function, diabetic patients with first ST-elevation myocardial infarction had reduced left ventricular systolic function, measured with speckle-tracking strain, compared with non-diabetic patients at baseline and at 6-month follow up, despite similar left ventricular ejection fraction in both groups. Similarly, according to the ischemic cascade, diastolic function is expected to be affected with variable degrees among diabetic, prediabetic and non-diabetic ST-elevation myocardial infarction patients.

Timmer et al, studied the effect of admission stress hyperglycemia and that of chronic hyperglycemia (elevated levels of HbA1c in patients with undiagnosed diabetes mellitus) on ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention; both elevated glucose and HbA1c levels were associated with adverse outcomes. However elevated glucose but not elevated HbA1c was associated with larger enzymatic infarct size and high early mortality.

Furthermore, Ota et al, demonstrated the association between stress hyperglycemia and the development of microvascular obstruction using late gadolinium enhancement - cardiovascular magnetic resonance imaging, suggesting that hyperglycemic control immediately after admission might reduce the incidence of microvascular obstruction.

This study is designed to explore the impact of the glycemic state on the in-hospital and short term outcomes of patients with ST-elevation myocardial infarction undergoing reperfusion therapy in two separate arms; those with known diabetes mellitus and those without known diagnosis of diabetes mellitus, and then comparing results among those with controlled diabetes mellitus, uncontrolled diabetes mellitus and newly diagnosed diabetes mellitus. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03266978
Study type Observational
Source Assiut University
Contact Amr Youssef, MD
Phone 00201006554042
Email amryoussef111@yahoo.com
Status Not yet recruiting
Phase N/A
Start date January 2018
Completion date July 2019

See also
  Status Clinical Trial Phase
Recruiting NCT05601999 - Study of Efficacy and Safety of GNR-060 vs Metalyse in Patients With ST Elevation Myocardial Infarction Phase 3
Recruiting NCT06147986 - Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells as an Add-On Treatment for Acute ST-elevation Myocardial Infarction (STEMI) Patients Phase 2
Not yet recruiting NCT05881382 - Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction Phase 3
Enrolling by invitation NCT02615015 - SNPs in the DNase 1 Gene Impair Its Activity and Are Increased in a STE-ACS Patient Cohort Compared to Healthy Controls N/A
Recruiting NCT05812963 - IVUS Versus FFR for Non-infarct Related Artery Lesions in Patients With Multivessel Disease and Acute STEMI N/A
Recruiting NCT05554588 - Intrathrombus Thrombolysis Versus Aspiration Thrombectomy During Primary PCI N/A
Recruiting NCT05450757 - Shanghai ST-segment Elevation Myocardial Infarction Cohort
Active, not recruiting NCT03278509 - Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART) Phase 4
Completed NCT03156699 - The Incidence, Effect and Persistence of Fragmented-QRS, in Patients Presenting With ST-Elevation Myocardial Infarction
Not yet recruiting NCT03263468 - Revascularization StrategIes for ST Elevation Myocardial Infarction Trial N/A
Not yet recruiting NCT03266328 - Procedure and In-hospital Outcome of Patients Under 40 Years Old Undergoing Primary Percutaneous Coronary Intervention for Acute ST Elevated Myocardial Infarction in Assiut University N/A
Enrolling by invitation NCT04970238 - Effect of Levosimendan on Left Ventricular Systolic Function and Heart Failure After PCI in Patients With Acute Anterior Myocardial Infarction Phase 4
Recruiting NCT02557217 - NP202 for Treatment of Post -STEMI Left Ventricular Systolic Dysfunction Phase 2
Recruiting NCT02224534 - Ticagrelor Versus Clopidogrel in Left Ventricular Remodeling After ST-segment Elevation Myocardial Infarction Phase 4
Completed NCT01136187 - Trial Comparing Radial and Femoral Approach in Primary Percutaneous Coronary Intervention (PCI) N/A
Not yet recruiting NCT04068116 - Impact of Ischemic Post-conditioning N/A
Not yet recruiting NCT04063345 - Long-term Clinical Outcomes of intraVascular Ultrasound-guided vs Angiography-guided Primary pErcutaneous Intervention in Patients With Acute ST Segment Elevated Myocardial Infarction Phase 2/Phase 3
Active, not recruiting NCT03646357 - BEtablocker Treatment After Acute Myocardial Infarction in Patients Without Reduced Left Ventricular Systolic Function Phase 4
Completed NCT03984071 - The Predictive Value of eGFR for Adverse Cardiovascular Events in Patients With STEMI
Completed NCT03740776 - The Eosinophils Percentage Predicts In-hospital Major Adverse Cardiac Events in STEMI Patients After PCI